Table 2 clinical characteristics and outcomes of select BsAbs in diffuse large B cell lymphoma (DLBCL).
From: Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
BsAb | Target | Schedule and logistics | Population | Results | Grade ≥3 AEs | FDA indication |
|---|---|---|---|---|---|---|
Epcoritamab | CD20xCD3 | SC, weekly (C1-C3), every 2W (C4–C9), every 4WC ≥ 10. Given till progression Steroid Ppx | ≥2 PLT including ASCT and CAR-T | ORR 63.1% (99/157) CR 38.9% (61/157) DOR 12 m | Any 61.1%, AEs leading to termination 7%, CRS 2.5%, ICANS 0.6%, TLS 1.3% | Accelerated approval ≥2 PLT in r/rDLBCL, NOS, T-iNHL and HGBCL. |
Mosunetuzumab | CD20xCD3 | IV, C1D1: 1 mg; C1D8 2 mg; C1D15 and C2D1: 60 mg; C3 + D1: 30 mg. (fixed duration up to C8 for pts in CR and C17 for pts in PR/SD) | ≥2 PLT including ASCT and CAR-T Types: DLBCL, T-FL | ORR 42.0% (37/88) CR 23.9% (21/88) DOR 7 m PFS 3.2 m OS 11.5 m | Any 58%, AEs leading to termination 4.5%, CRS 2.3%, ICANS 0%, grade 5 TRAEs 1.1% | Not yet approved for DLBCL |
Glofitamab | CD20xCD3 | IV, weekly step up dosing starting on d8 (2.5 mg), d15 (10 mg) of C1, followed by a dose of 30 mg on d1 of C2–12 (fixed duration) Obinutuzumab pretreatment 7d before therapy | ≥2 PLT including ASCT and CAR-T Types: DLBCL, HGBCL, PMBCL, T-FL | ORR 51.1% (80/155) CR 39% (60/155) DOR 18.4 m PFS 4.9 m, OS 11.5 m | Any 56%, AEs leading to termination 9%, CRS 3.9%, ICANS 3%, TLS 1%, FN 3% | Accelerated approval ≥2 PLT in r/r DLBCL, NOS or T-FL LBCL |
Odronextamab | CD20xCD3 | IV, weekly (C1–C4) then every 2 weeks Steroid Ppx | ≥2 PLT, including prior CAR-T | ORR 52% (66/127) CR 31% (39/127) Duration of CR 17.9 m | Any 78.6%, AEs leading to termination 10%, CRS 1%, ICANS 0%, | Not yet approved for DLBCL |
Palmotamaba | CD20xCD3 | IV, ≥2 cycles if PR achievd | Median number of prior lines:4, 50% CAR-T exposed | OR 47.4% (9/19 pts) CR 26.3% (5/19 pts) | Any 77.8%, AEs leading to termination 13.9%CRS 0% | Not yet approved for DLBCL |
